People

Caryn Lerman, PhD, became director of the University of Southern California (USC) Norris Comprehensive Cancer Center in Los Angeles, as well as a professor of psychiatry and behavioral sciences at the USC Keck School of Medicine, in March. Previously, Lerman worked as a professor of cancer research and vice dean for strategic initiatives at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia. Prior to that, she served as senior deputy director and interim director of the Abramson Cancer Center and co-director of the Translational Neuroscience Center, both at Perelman. As a cancer-prevention researcher, she published one of the first studies on genetic influences on tobacco use.

On April 1, Anil Rustgi, MD, began his role as director of the Herbert Irving Comprehensive Cancer Center at Columbia University and New York-Presbyterian/Columbia University Irving Medical Center in New York, NY. He is also associate dean of oncology and a professor of medicine at the Vagelos College of Physicians and Surgeons at Columbia. Previously, he was chief of gastroenterology and a professor of medicine and genetics at Perelman. Rustgi studies gastrointestinal cancers, including how cellular processes and the tumor microenvironment contribute to the disease.

Daniel O'Day, MBA, became CEO and chairman of the board at Gilead on March 1, succeeding CEO John Milligan, PhD, and chairman John Martin, PhD. O'Day joined Roche in 1987, serving in a variety of roles, including president and CEO of Roche Molecular Diagnostics, chief operating officer of Roche Diagnostics, and most recently, CEO of Roche Pharmaceuticals. O'Day earned his MBA from Columbia University.

For more news on cancer research, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.